New tests aimed at faster evaluation of traumatic brain injury (TBI) have been launched by long-standing immunoassays company, DRG Instruments.
DRG has launched a neuroscience division which has announced the roll out of its “fully automated” tests for evaluating TBI, the GFAP and UCH-L1 combo Tests.
These tests are designed for use on DRG’s platform, DxDATA, enabling the measurement of glial fibrillary acidic protein (GFAP) and UCH-L1 blood levels within 30 minutes when patients’ serum samples are collected within 12 hours of suspected TBI.
“We are excited to bring these innovative TBI solutions to the global market,” said Joerg Schloesser, managing director and VP of commercial at DRG.
“By leveraging automated testing and rapid turnaround times, we can help healthcare professionals make quicker, more informed decisions. Our mission is to advance patient care for those affected by traumatic brain injuries worldwide.”
DRG’s TBI tests are CE-marked and have been verified to meet CLSI (Clinical and Laboratory Standards Institute) requirements.
They are intended for use in a clinical laboratory setting and are indicated for patients aged 18 years or older.
DRG Instruments GmbH, was established in 1973. Since 1990, DRG it has developed and manufactured immunoassays for routine and research applications, with distribution partners in over 120 countries.
